Literature DB >> 26609943

Immune suppressive mechanisms in the tumor microenvironment.

David H Munn1, Vincenzo Bronte2.   

Abstract

Effective immunotherapy, whether by checkpoint blockade or adoptive cell therapy, is limited in most patients by a key barrier: the immunosuppressive tumor microenvironment. Suppression of tumor-specific T cells is orchestrated by the activity of a variety of stromal myeloid and lymphoid cells. These often display inducible suppressive mechanisms that are triggered by the same anti-tumor inflammatory response that the immunotherapy intends to create. Therefore, a more comprehensive understanding of how the immunosuppressive milieu develops and persists is critical in order to harness the full power of immunotherapy of cancer.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26609943      PMCID: PMC5627973          DOI: 10.1016/j.coi.2015.10.009

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  56 in total

1.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

Review 2.  Regulatory T cells in cancer immunotherapy.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Curr Opin Immunol       Date:  2014-01-14       Impact factor: 7.486

3.  Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

Authors:  Soranobu Ninomiya; Neeharika Narala; Leslie Huye; Shigeki Yagyu; Barbara Savoldo; Gianpietro Dotti; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Carlos A Ramos
Journal:  Blood       Date:  2015-05-04       Impact factor: 22.113

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 5.  Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Authors:  Douglas Marvel; Dmitry I Gabrilovich
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

6.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

Review 7.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

8.  Aire-dependent thymic development of tumor-associated regulatory T cells.

Authors:  Sven Malchow; Daniel S Leventhal; Saki Nishi; Benjamin I Fischer; Lynn Shen; Gladell P Paner; Ayelet S Amit; Chulho Kang; Jenna E Geddes; James P Allison; Nicholas D Socci; Peter A Savage
Journal:  Science       Date:  2013-03-08       Impact factor: 47.728

9.  Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.

Authors:  Nikhil S Joshi; Elliot H Akama-Garren; Yisi Lu; Da-Yae Lee; Gregory P Chang; Amy Li; Michel DuPage; Tuomas Tammela; Natanya R Kerper; Anna F Farago; Rebecca Robbins; Denise M Crowley; Roderick T Bronson; Tyler Jacks
Journal:  Immunity       Date:  2015-09-01       Impact factor: 31.745

10.  The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.

Authors:  Madhav D Sharma; Rahul Shinde; Tracy L McGaha; Lei Huang; Rikke B Holmgaard; Jedd D Wolchok; Mario R Mautino; Esteban Celis; Arlene H Sharpe; Loise M Francisco; Jonathan D Powell; Hideo Yagita; Andrew L Mellor; Bruce R Blazar; David H Munn
Journal:  Sci Adv       Date:  2015-11-06       Impact factor: 14.136

View more
  152 in total

1.  Central tolerance: what you see is what you don't get!

Authors:  Douglas G Millar; Pamela S Ohashi
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

Review 2.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

3.  Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.

Authors:  Zhuoya Wan; Jingjing Sun; Jieni Xu; Pearl Moharil; Jing Chen; Junchi Xu; Junjie Zhu; Jiang Li; Yixian Huang; Pengfei Xu; Xiaochao Ma; Wen Xie; Binfeng Lu; Song Li
Journal:  Acta Biomater       Date:  2019-03-28       Impact factor: 8.947

Review 4.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

Review 5.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

Review 6.  Genomics of adult and pediatric solid tumors.

Authors:  Zahraa Rahal; Farah Abdulhai; Humam Kadara; Raya Saab
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

7.  Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages.

Authors:  Emmanuelle Alaluf; Benoît Vokaer; Aurélie Detavernier; Abdulkader Azouz; Marion Splittgerber; Alice Carrette; Louis Boon; Frédérick Libert; Miguel Soares; Alain Le Moine; Stanislas Goriely
Journal:  JCI Insight       Date:  2020-06-04

Review 8.  Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.

Authors:  Chung-Han Lee; Roman Yelensky; Karin Jooss; Timothy A Chan
Journal:  Trends Immunol       Date:  2018-05-08       Impact factor: 16.687

9.  Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Authors:  Timothy E Krueger; Daniel L J Thorek; Alan K Meeker; John T Isaacs; W Nathaniel Brennen
Journal:  Prostate       Date:  2018-11-28       Impact factor: 4.104

10.  Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer.

Authors:  Lifeng Li; Liping Wang; Jieyao Li; Zhirui Fan; Li Yang; Zhen Zhang; Chaoqi Zhang; Dongli Yue; Guohui Qin; Tengfei Zhang; Feng Li; Xinfeng Chen; Yu Ping; Dan Wang; Qun Gao; Qianyi He; Lan Huang; Hong Li; Jianmin Huang; Xuan Zhao; Wenhua Xue; Zhi Sun; Jingli Lu; Jane J Yu; Jie Zhao; Bin Zhang; Yi Zhang
Journal:  Cancer Res       Date:  2018-01-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.